Al­bert Bourla has some plans for Pfiz­er's huge Covid cash haul. Hint: 'Ac­qui­si­tions are very much in the card­s'

To­day was Pfiz­er CEO Al­bert Bourla’s chance to rel­ish the mar­ket suc­cess of its Covid vac­cine and drug and what a fresh flow of $54 bil­lion-plus from the pan­dem­ic fran­chise this year can do for the com­pa­ny. First on the list? The BD team is buck­ling down to pick up the pace for more deals in the year ahead.

This is clear­ly Aamir Ma­lik’s turn to shine, af­ter tak­ing the BD reins from John Young last sum­mer as he com­plet­ed a 34-year ca­reer run at Pfiz­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER